Company
MannKind Corporation
Headquarters: Westlake Village, CA, United States
Founded: 1991
Employees: 348
CEO: Dr. Michael E. Castagna
Market Cap
$1.40 Billion
USD as of July 1, 2024
MannKind Corporation Categories
United States Healthcare BiotechnologyUnited States Healthcare United States Biotechnology
Top Competitors by Market Capitalization
Industry: Biotechnology
| Company | Market Cap (USD) |
|---|---|
| Novo Nordisk | $622.07 B |
| Vertex Pharmaceuticals Incorporated | $121.36 B |
| Regeneron Pharmaceuticals, Inc. | $115.11 B |
| CSL Limited | $95.75 B |
| Marinomed Biotech AG | $75.67 B |
Sector:
| Company | Market Cap (USD) |
|---|---|
| Lilly | $808.65 B |
| Novo Nordisk | $622.07 B |
| UnitedHealth Group | $450.89 B |
| Johnson & Johnson | $350.63 B |
| Merck | $318.75 B |
Detailed Description
MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes. It also promotes Thyquidity to adult and pediatric endocrinologists, and other healthcare providers for the treatment of hypothyroidism. The company has a license and collaboration agreement with United Therapeutics Corporation. It also has an agreement with NRx Pharmaceuticals to develop a dry powder formulation of ZYESAMI (aviptadil), a synthetic form of human vasoactive intestinal peptide to help protect cells against inflammatory conditions. MannKind Corporation was incorporated in 1991 and is headquartered in Westlake Village, California.
Top 1-year algo backtest: +265.99%
$10,000 in October 2023 would now be $36,599 by following this algorithm daily at market close.
Use AI to boost your investing & swing trading, now!
Try Disfold DeepFinance FREE
Stocks & Indices
MannKind Corporation has the following listings and related stock indices.
Stock: NASDAQ: MNKD wb_incandescent
Stock: FSX: NNFN wb_incandescent
Key People
Founder(s): Alfred E. Mann
Kent Kresa (Chairman) Dr. Michael E. Castagna (CEO)
Financials
Revenue: US$63.038 million (2019)
Operating income: −US$44.597 million (2019)
Net income: −US$51.903 million (2019)
Total assets: $93.725 million (2019)
Total equity: $284.252 million (2019)